HOMEProfessor Kenji Hirayama

Faculty

Professor Kenji Hirayama

Speciality / Research theme / Keywords
Immunogenetics, Parasitology
Supervision
Masters ProgrammeDoctoral Programme

Qualifications

MD, PhD

Personal/work Web page addresses

http://www.tm.nagasaki-u.ac.jp/hiraken/

Research gate or Linked-in account links

https://www.researchgate.net/profile/Kenji_Hirayama

Affiliation(s)

Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University

Background

  • 2001-： Professor, NEKKEN, Nagasaki University
  • 1995-2001：Professor, Saitama Medical University
  • 1989-92: Research Fellow, Harvard School of Public Health
  • 1985-89: Medical Institute of Bioregulation, Kyushu University
  • 1981-85: PhD course, Human Genetics, Medical Research Institute, Tokyo Medical and Dental University

Teaching

Current roles: Course Director of Health Innovation, Responsible for Immunology and Biotechnology courses Teaching experience: Course Director of Master of Tropical Medicine, Nagasaki University Graduate school of Biomedical Science. Medical Parasitology, Clinical Immunology, Tropical Infectious diseases, Tropical Public Health, Research Ethics, Vaccinology, Clinical Product Development

Research

Vaccine development for malaria, Dengue, and Chagas Disease using DNA or recombinant vaccine. (Hisamitsu, Pasteur Paris, European Vaccine Initiative) Drug development for malaria and trypanosomiasis using compound designing or herbal medicine. (Astellas, National Institute of Advanced Industrial Science and Technology, Institute of Natural Medicine Toyama University, Thammasat University) HLA regulated Immune responsiveness against malaria, dengue, Chagas and Schistosomiasis. (Tokyo Med Dent University, Research Institute of Tropical Medicine, Philippines, Pasteur Institute Ho Chi Minh, Kenya Medical Research Institute) http://www.tm.nagasaki-u.ac.jp/hiraken/english/index.html

The country/countries where you work currently

  • France
  • Germany
  • UK
  • Thailand
  • Vietnam
  • Myanmar
  • Philippines
  • Kenya
  • Bolivia
  • Paraguay
  • DRCongo

Five MOST IMPORTANT/INTERESTING recent publications

  1. Kinoshita T, Espino F, Bunagan R, Lim D, Daga C, Parungao S, Balderian A, Micu K, Laborera R, Basilio R, Inobaya M, Baquilod M, Dy M, Chiba H, Matsumoto T, Nakayama T, Kita K, Hirayama K.　 First malaria in pregnancy followed in Philippine real-world setting: proof-of-concept of probabilistic record linkage between disease surveillance and hospital administrative data. Trop Med Health. 2024; 52(1):17.
  2. Nakamae S, Miyagawa S, Ogawa K, Kamiya M, Taniguchi M, Ono A, Kawaguchi M, Teklemichael AA, Jian JY, Araki T, Katagami Y, Mukai H, Annoura T, Yui K, Hirayama K, Kawakami S, Mizukami S. Induction of liver-resident memory T cells and protection at liver-stage malaria by mRNA-containing lipid nanoparticles. Front Immunol. 2023;14:1116299. 
  3. Mizuta S, Mosaddeque F, Tun MMN, Teklemichael AA, Taniguchi M, Hosokawa M, Yamaguchi T, Makau J, Huy NT, Mizukami S, Nishida N, Morita K, Hirayama K. Challenges Based on Antiplasmodial and Antiviral Activities of 7-Chloro-4-aminoquinoline Derivatives. ChemMedChem. 2023; 18(7):e202200586.
  4. Tayama Y, Mizukami S, Toume K, Komatsu K, Yanagi T, Nara T, Tieu P, Huy NT, Hamano S, Hirayama K. Anti-Trypanosoma cruzi activity of Coptis rhizome extract and its constituents. Trop Med Health. 2023; 51(1):12.
  5. Iglesias Rodríguez IM, Miura S, Maeda T, Imai K, Smith C, Vasquez Velasquez C, Honda S, Hirayama K. Analysis of the Chagas disease situation in Japan: a cross sectional study and cost-effectiveness analysis of a Chagas disease screening program. Lancet Reg Health West Pac. 2022; 31:100574. 

Message

I am teaching Biotechnology, Immunology with Prof Yui and Research Ethics with Prof Juntra. My research area is immunology, human genetics and product development in tropical infectious diseases, and I am currently interested in research that contributes to the prevention and treatment of tropical infectious diseases with high morbidity and mortality. Production of vaccines and drugs has been my dream ever since I decided to be a doctor. I realized that such research should be pursued as a joint team gathering the forces of academia, public domains and private sectors, the so called PPP. For more than ten years, I have been involved in such projects for the control of malaria, dengue fever, Chagas disease and schistosomiasis. I hope you will be interested in our activity.

PAGE TOP